Terms: = Pancreatic cancer AND HRAS, K-ras, 3265, ENSG00000174775, HRAS1, RASH1, c-bas/has, P01112, N-ras
1072 results:
1. k-ras(V12) differentially affects the three Akt isoforms in lung and pancreatic carcinoma cells and upregulates E-cadherin and NCAM via Akt3.
Geißert R; Lammert A; Wirth S; Hönig R; Lohfink D; Unger M; Pek D; Schlüter K; Scheftschik T; Smit DJ; Jücker M; Menke A; Giehl K
Cell Commun Signal; 2024 Jan; 22(1):85. PubMed ID: 38291468
[TBL] [Abstract] [Full Text] [Related]
2. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
[TBL] [Abstract] [Full Text] [Related]
3. Surgeon-Dependent Variability in Cost of Gastrointestinal Operations in a Single cancer Center.
Sarkar J; Roehner RP; Proulx MJ; Schwarz RE
J Surg Res; 2024 Mar; 295():666-672. PubMed ID: 38113610
[TBL] [Abstract] [Full Text] [Related]
4. k-ras gene mutation analysis to diagnosis pancreatic adenocarcinoma from endoscopic ultrasound-guided tissue acquisition; a systematic review and meta-analysis.
Tamura T; Ashida R; Wan K; Shimokawa T; Kitano M
Pancreatology; 2024 Feb; 24(1):78-87. PubMed ID: 38042675
[TBL] [Abstract] [Full Text] [Related]
5. Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer.
Rowell MC; Deschênes-Simard X; Lopes-Paciencia S; Le Calvé B; Kalegari P; Mignacca L; Fernandez-Ruiz A; Guillon J; Lessard F; Bourdeau V; Igelmann S; Duman AM; Stanom Y; Kottakis F; Deshpande V; Krizhanovsky V; Bardeesy N; Ferbeyre G
Cell Cycle; 2023 Oct; 22(19):2172-2193. PubMed ID: 37942963
[TBL] [Abstract] [Full Text] [Related]
6. Synergistic effect of antagonists to KRas4B/PDE6 molecular complex in pancreatic cancer.
Briseño-Díaz P; Schnoor M; Bello-Ramirez M; Correa-Basurto J; Rojo-Domínguez A; Arregui L; Vega L; Núñez-González E; Palau-Hernández LA; Parra-Torres CG; García Córdova OM; Zepeda-Castilla E; Torices-Escalante E; Domínguez-Camacho L; Xoconostle-Cazares B; Meraz-Ríos MA; Delfín-Azuara S; Carrión-Estrada DA; Villegas-Sepúlveda N; Hernández-Rivas R; Thompson-Bonilla MDR; Vargas M
Life Sci Alliance; 2023 Dec; 6(12):. PubMed ID: 37813486
[TBL] [Abstract] [Full Text] [Related]
7. The inhibition of pancreatic cancer progression by k-ras-overexpressing mesenchymal stem cell-derived secretomes.
Huo Q; Li K; Sun X; Zhuang A; Minami K; Tamari K; Ogawa K; Fishel ML; Li BY; Yokota H
Sci Rep; 2023 Sep; 13(1):15036. PubMed ID: 37699930
[TBL] [Abstract] [Full Text] [Related]
8. A new ferrocene derivative blocks k-ras localization and function by oxidative modification at His95.
Rehl KM; Selvakumar J; Pitsch RL; Hoang D; Arumugam K; Harshman SW; Gorfe AA; Cho KJ
Life Sci Alliance; 2023 Nov; 6(11):. PubMed ID: 37666666
[TBL] [Abstract] [Full Text] [Related]
9. Small molecular inhibitors for KRAS-mutant cancers.
Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
[TBL] [Abstract] [Full Text] [Related]
10. Nimotuzumab Plus Gemcitabine for k-ras Wild-Type Locally Advanced or Metastatic pancreatic cancer.
Qin S; Li J; Bai Y; Wang Z; Chen Z; Xu R; Xu J; Zhang H; Chen J; Yuan Y; Liu T; Yang L; Zhong H; Chen D; Shen L; Hao C; Fu D; Cheng Y; Yang J; Wang Q; Qin B; Pan H; Zhang J; Bai X; Zheng Q
J Clin Oncol; 2023 Nov; 41(33):5163-5173. PubMed ID: 37647576
[TBL] [Abstract] [Full Text] [Related]
11. Exploring switch II pocket conformation of KRAS(G12D) with mutant-selective monobody inhibitors.
Akkapeddi P; Hattori T; Khan I; Glasser E; Koide A; Ketavarapu G; Whaby M; Zuberi M; Teng KW; Lefler J; Maso L; Bang I; Ostrowski MC; O'Bryan JP; Koide S
Proc Natl Acad Sci U S A; 2023 Jul; 120(28):e2302485120. PubMed ID: 37399416
[TBL] [Abstract] [Full Text] [Related]
12. Ral GTPase promotes metastasis of pancreatic ductal adenocarcinoma via elevation of TGF-β1 production.
Cao M; Li X; Trinh DA; Yoshimachi S; Goto K; Sakata N; Ishida M; Ohtsuka H; Unno M; Wang Y; Shirakawa R; Horiuchi H
J Biol Chem; 2023 Jun; 299(6):104754. PubMed ID: 37116704
[TBL] [Abstract] [Full Text] [Related]
13. The Mutational, Prognostic, and Therapeutic Landscape of Neuroendocrine Neoplasms.
Liu M; Li N; Tang H; Chen L; Liu X; Wang Y; Lin Y; Luo Y; Wei S; Wen W; Chen M; Wang J; Zhang N; Chen J
Oncologist; 2023 Sep; 28(9):e723-e736. PubMed ID: 37086484
[TBL] [Abstract] [Full Text] [Related]
14. Identification of novel peptide inhibitors for oncogenic KRAS G12D as therapeutic options using mutagenesis-based remodeling and MD simulations.
Samad A; Khurshid B; Mahmood A; Rehman AU; Khalid A; Abdalla AN; Algarni AS; Wadood A
J Biomol Struct Dyn; 2023; 41(22):13425-13437. PubMed ID: 37010994
[TBL] [Abstract] [Full Text] [Related]
15. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors.
Anthiya S; Öztürk SC; Yanik H; Tavukcuoglu E; Şahin A; Datta D; Charisse K; Álvarez DM; Loza MI; Calvo A; Sulheim E; Loevenich S; Klinkenberg G; Schmid R; Manoharan M; Esendağlı G; Alonso MJ
J Control Release; 2023 May; 357():67-83. PubMed ID: 36921725
[TBL] [Abstract] [Full Text] [Related]
16. hras overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Liverani C; Spadazzi C; Ibrahim T; Pieri F; Foca F; Calabrese C; De Vita A; Miserocchi G; Cocchi C; Vanni S; Ercolani G; Cavaliere D; Ranallo N; Chiadini E; Prisinzano G; Severi S; Sansovini M; Martinelli G; Bongiovanni A; Mercatali L
Front Endocrinol (Lausanne); 2022; 13():1045038. PubMed ID: 36743926
[TBL] [Abstract] [Full Text] [Related]
17. Investigation into the content of red material in EUS-guided pancreatic cancer biopsies.
Lin MY; Su YY; Yu YT; Huang CJ; Sheu BS; Chang WL
Gastrointest Endosc; 2023 Jun; 97(6):1083-1091.e1. PubMed ID: 36720289
[TBL] [Abstract] [Full Text] [Related]
18. Lipid raft protein flotillin-1 is important for the interaction between SOS1 and H-Ras/k-ras, leading to Ras activation.
Jin H; Koh M; Lim H; Yong HY; Kim ES; Kim SY; Kim K; Jung J; Ryu WJ; Choi KY; Moon A
Int J Cancer; 2023 May; 152(9):1933-1946. PubMed ID: 36691829
[TBL] [Abstract] [Full Text] [Related]
19. Nanoformulation of the k-ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.
Sakamoto K; Qi Y; Miyako E
Sci Rep; 2023 Jan; 13(1):518. PubMed ID: 36627374
[TBL] [Abstract] [Full Text] [Related]
20. Silencing effects of mutant RAS signalling on transcriptomes.
Sers C; Schäfer R
Adv Biol Regul; 2023 Jan; 87():100936. PubMed ID: 36513579
[TBL] [Abstract] [Full Text] [Related]
[Next]
